What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Sat, May 30, 2026 astatine 12:56 PM CDT 4 min read

On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 cardinal commercialized based connected quarterly mean pricing.

What happened

According to an SEC filing dated May 14, 2026, Krensavage Asset Management accrued its involvement successful Ultragenyx Pharmaceutical by 241,245 shares during the archetypal quarter. The estimated worth of shares acquired was $5.43 million, calculated utilizing the mean closing terms for the period. The money finished the 4th with 390,879 shares valued astatine $8.19 million. The position’s quarter-end worth roseate by $4.75 million, a fig that includes some trading enactment and terms changes.

What other to cognize

The bargain brings Ultragenyx Pharmaceutical to 3.2% of Krensavage Asset Management’s 13F assets arsenic of March 31, 2026.
Top 5 holdings aft the filing:
- NASDAQ:UTHR: $49.98 cardinal (19.5% of AUM)
- NASDAQ:ENTA: $36.20 cardinal (14.2% of AUM)
- NASDAQ:JAZZ: $31.73 cardinal (12.4% of AUM)
- NASDAQ:BMRN: $29.64 cardinal (11.6% of AUM)
- NASDAQ:EXEL: $17.83 cardinal (7.0% of AUM)
As of Friday, RARE shares were priced astatine $23.94, down 32% implicit the past twelvemonth and good underperforming the S&P 500, which is alternatively up astir 28%.

Company overview

Metric

Value

Revenue (TTM)	$670 million
Net Income (TTM)	($609 million)
Market Capitalization	$2.4 billion
Price (as of Friday)	$23.94

Company snapshot

Ultragenyx develops and commercializes biologic and tiny molecule therapies for uncommon and ultra-rare familial diseases, with marketed products including Crysvita, Mepsevii, Dojolvi, and Evkeeza.
The institution generates gross chiefly done merchandise income and strategical collaborations, leveraging a pipeline of cistron therapies and monoclonal antibodies targeting niche diligent populations.
Primary customers are healthcare providers, specialty pharmacies, and hospitals serving patients with uncommon metabolic and familial disorders successful North America, Europe, and prime planetary markets.

Ultragenyx Pharmaceutical Inc. is simply a biopharmaceutical institution focused connected the improvement and commercialization of therapies for uncommon and ultra-rare familial diseases. The institution combines a portfolio of approved products with a robust pipeline of objective candidates, aiming to code important unmet aesculapian needs. Its strategy centers connected leveraging technological expertise and strategical partnerships to bring innovative treatments to underserved diligent populations globally.

What this transaction means for investors

Ultragenyx shares person struggled implicit the past year, but Krensavage appears to beryllium focusing connected the long-term. The company's commercialized concern is already producing meaningful scale. Total gross climbed 20% successful 2025 to $673 million, led by Crysvita gross of $481 cardinal and continued maturation from Dojolvi and Evkeeza. Management expects current-product gross to summation again successful 2026, guiding for $730 cardinal to $760 cardinal adjacent earlier factoring successful immoderate contributions from imaginable caller merchandise launches.

The bigger story, however, whitethorn beryllium what's coming next. CEO Emil Kakkis called 2026 an "important turning point" arsenic Ultragenyx approaches 2 imaginable approvals and a pivotal Phase 3 information readout for GTX-102 successful Angelman syndrome. Those catalysts could materially grow the company's commercialized footprint.

Management is besides trying to amended the fiscal profile. The institution announced a restructuring program that includes a 10% workforce simplification and expects probe and improvement spending to autumn importantly by 2027. Combined with increasing merchandise revenue, Ultragenyx reiterated its extremity of reaching profitability successful 2027. And with that successful mind, this acquisition looks similar a imaginable stake that Ultragenyx is approaching an inflection point.

Read Entire Article